Literature DB >> 16818663

Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population.

Nina Joshi1, Laura Lee Johnson, Wen-Qiang Wei, Christian C Abnet, Zhi-Wei Dong, Philip R Taylor, Paul J Limburg, Sanford M Dawsey, Ernest T Hawk, You-Lin Qiao, Ilan R Kirsch.   

Abstract

A randomized, double-blinded, placebo-controlled 2 x 2 factorial chemoprevention trial was conducted in Linxian, China to assess the effects of selenomethionine and celecoxib on the natural history of esophageal squamous dysplasia. Results from this study indicated that asymptomatic adults with mild dysplasia were more likely to show an improvement when treated with selenomethionine compared with placebo (P = 0.02). Prompted by this finding, we examined the molecular profiles associated with regression and progression of dysplastic lesions in normal mucosa from 29 individuals, a subset of the Linxian cohort, using the Affymetrix U133A chip. Twenty differentially expressed genes were associated with regression and 129 were associated with progression when we compared the change in gene expression over time. Genes associated with immune response (n = 15), cell cycle (n = 15), metabolism (n = 15), calcium transport or calcium ion activity (n = 10), regulation of transcription (n = 9), signal transduction (n = 7), cytoskeleton and microtubules (n = 5), nucleotide processing and biosynthesis (n = 4), G-coupled signaling (n = 4), and apoptosis (n = 3) were present in the list of 149 genes. Using the Expression Analysis Systematic Explorer pathway analysis program, only the immune response pathway was significantly overrepresented among these 149 genes. Individuals whose lesions regressed seemed to have higher expression of genes associated with immune stimulation, such as antigen presentation, survival of T cells, and T-cell activation (HLA-DRA, HLA-DPA1, HLA-DBQ1, CD58, and FCER1A). In contrast, individuals whose lesions progressed had higher expression of genes involved in immune suppression and inflammation (CNR2, NFATC4, NFRKB, MBP, INHBB, CMKLR1, CRP, ORMS, SERPINA7, and SERPINA1). These data suggest that local and systemic immune responses may influence the natural history of esophageal squamous dysplasia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16818663     DOI: 10.1158/0008-5472.CAN-06-0662

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  cDNA microarray analysis of esophageal cancer: discoveries and prospects.

Authors:  Yutaka Shimada; Fumiaki Sato; Kazuharu Shimizu; Gozoh Tsujimoto; Kazuhiro Tsukada
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-07-14

2.  Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma.

Authors:  Mehdi Farshchian; Atte Kivisaari; Risto Ala-Aho; Pilvi Riihilä; Markku Kallajoki; Reidar Grénman; Juha Peltonen; Taina Pihlajaniemi; Ritva Heljasvaara; Veli-Matti Kähäri
Journal:  Am J Pathol       Date:  2011-07-01       Impact factor: 4.307

3.  Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.

Authors:  Xifeng Wu; Yuanqing Ye; Rafael Rosell; Christopher I Amos; David J Stewart; Michelle A T Hildebrandt; Jack A Roth; John D Minna; Jian Gu; Jie Lin; Shama C Buch; Tomoko Nukui; Jose Luis Ramirez Serrano; Miquel Taron; Adrian Cassidy; Charles Lu; Joe Y Chang; Scott M Lippman; Waun Ki Hong; Margaret R Spitz; Marjorie Romkes; Ping Yang
Journal:  J Natl Cancer Inst       Date:  2011-04-11       Impact factor: 13.506

4.  Serum cytokine analysis in a positive chemoprevention trial: selenium, interleukin-2, and an association with squamous preneoplastic disease.

Authors:  Mark J Roth; Hormuzd A Katki; Wen-Qiang Wei; You-Lin Qiao; Rachel Bagni; Guo-Qing Wang; Denise Whitby; Zhi-Wei Dong; Mitchell H Gail; Paul J Limburg; Carol A Giffen; Philip R Taylor; Sanford M Dawsey
Journal:  Cancer Prev Res (Phila)       Date:  2010-06-29

5.  Suppression of intestinal inflammation and inflammation-driven colon cancer in mice by dietary sphingomyelin: importance of peroxisome proliferator-activated receptor γ expression.

Authors:  Joseph C Mazzei; Hui Zhou; Bradley P Brayfield; Raquel Hontecillas; Josep Bassaganya-Riera; Eva M Schmelz
Journal:  J Nutr Biochem       Date:  2011-02-04       Impact factor: 6.048

6.  Fish oil alters tamoxifen-modulated expression of mRNAs that encode genes related to differentiation, proliferation, metastasis, and immune response in rat mammary tumors.

Authors:  Lucas Tadeu Bidinotto; Ricardo López de Cicco; Johana Erika Vanegas; Julia Santucci-Pereira; John Patrick Vanden Heuvel; Sharlene Washington; Cesar Aliaga; Haifang Xu; Irma H Russo; Andrea Manni; Karam El-Bayoumy; Jose Russo
Journal:  Nutr Cancer       Date:  2012       Impact factor: 2.900

7.  Second generation sequencing of the mesothelioma tumor genome.

Authors:  Raphael Bueno; Assunta De Rienzo; Lingsheng Dong; Gavin J Gordon; Colin F Hercus; William G Richards; Roderick V Jensen; Arif Anwar; Gautam Maulik; Lucian R Chirieac; Kim-Fong Ho; Bruce E Taillon; Cynthia L Turcotte; Robert G Hercus; Steven R Gullans; David J Sugarbaker
Journal:  PLoS One       Date:  2010-05-13       Impact factor: 3.240

8.  Integrative meta-analysis of differential gene expression in acute myeloid leukemia.

Authors:  Brady G Miller; John A Stamatoyannopoulos
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

9.  Gene expression profile of esophageal cancer in North East India by cDNA microarray analysis.

Authors:  Indranil Chattopadhyay; Sujala Kapur; Joydeep Purkayastha; Rupkumar Phukan; Amal Kataki; Jagadish Mahanta; Sunita Saxena
Journal:  World J Gastroenterol       Date:  2007-03-07       Impact factor: 5.742

10.  The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal cancer risk.

Authors:  Andrea Y Angstadt; Arthur Berg; Junjia Zhu; Paige Miller; Terryl J Hartman; Samuel M Lesko; Joshua E Muscat; Philip Lazarus; Carla J Gallagher
Journal:  Cancer       Date:  2013-04-10       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.